Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant versus placebo for microalbuminuria in overweight adults with type 2 diabetes on ramipril background therapy
2007-002077-31Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and Abdominal adiposity (ABCD) comparing Rimonabant with Placebo (2 arms). Primary endpoint: Mean change from baseline to month 9 in overnight urinary albumin excretion rate. Started Apr 2008; status: terminated.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2007-002077-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002077-31.